Key Points Pinometostat demonstrates first evidence of DOT1L target inhibition and clinical responses in a subset of MLL-r advanced leukemia patients. The observed safety profile of pinometostat shows potential for exploration of combination therapies in leukemia.
The TALE Homeodomain Protein Pbx2 Is Not Essential for Development and Long-Term Survival
Molecular and Cellular Biology | May 28, 2004 | Volume: 24 | Issue: 12 | Pages: 5324-5331